Advances in Omics Technologies in GBM
Glioblastoma multiforme (GBM) is one of the most lethal human cancers and poses a great challenge in the therapeutic interventions of GBM patients worldwide. Despite prominent recent advances in oncology, on an average GBM patients survive 12–15 months with conventional standard of care treatment. T...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Series: | Biomedical Research Journal |
| Subjects: | |
| Online Access: | http://www.brjnmims.org/article.asp?issn=2349-3666;year=2015;volume=2;issue=1;spage=6;epage=20;aulast=Maachani;type=0 |
| _version_ | 1818385297762680832 |
|---|---|
| author | Uday B Maachani Uma Shankavaram Kevin Camphausen Anita Tandle |
| author_facet | Uday B Maachani Uma Shankavaram Kevin Camphausen Anita Tandle |
| author_sort | Uday B Maachani |
| collection | DOAJ |
| description | Glioblastoma multiforme (GBM) is one of the most lethal human cancers and poses a great challenge in the therapeutic interventions of GBM patients worldwide. Despite prominent recent advances in oncology, on an average GBM patients survive 12–15 months with conventional standard of care treatment. To understand the pathophysiology of this disease, recently the research focus has been on omics-based approaches. Advances in high-throughput assay development and bioinformatic techniques have provided new opportunities in the molecular analysis of cancer omics technologies including genomics, transcriptomics, epigenomics, proteomics, and metabolomics. Further, the enormous addition and accessibility of public databases with associated clinical demographic information including tumor histology, patient response and outcome, have profoundly improved our knowledge of the molecular mechanisms driving cancer. In GBM, omics have significantly aided in defining the molecular architecture of tumorigenesis, uncovering relevant subsets of patients whose disease may require different treatments. In this review, we focus on the unique advantages of multifaceted omics technologies and discuss the implications on translational GBM research. |
| first_indexed | 2024-12-14T03:35:55Z |
| format | Article |
| id | doaj.art-4f33de0ee6f945aea1aa871f897a1d0d |
| institution | Directory Open Access Journal |
| issn | 2349-3666 2349-3674 |
| language | English |
| last_indexed | 2024-12-14T03:35:55Z |
| publishDate | 2015-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Biomedical Research Journal |
| spelling | doaj.art-4f33de0ee6f945aea1aa871f897a1d0d2022-12-21T23:18:37ZengWolters Kluwer Medknow PublicationsBiomedical Research Journal2349-36662349-36742015-01-012162010.4103/2349-3666.240621Advances in Omics Technologies in GBMUday B MaachaniUma ShankavaramKevin CamphausenAnita TandleGlioblastoma multiforme (GBM) is one of the most lethal human cancers and poses a great challenge in the therapeutic interventions of GBM patients worldwide. Despite prominent recent advances in oncology, on an average GBM patients survive 12–15 months with conventional standard of care treatment. To understand the pathophysiology of this disease, recently the research focus has been on omics-based approaches. Advances in high-throughput assay development and bioinformatic techniques have provided new opportunities in the molecular analysis of cancer omics technologies including genomics, transcriptomics, epigenomics, proteomics, and metabolomics. Further, the enormous addition and accessibility of public databases with associated clinical demographic information including tumor histology, patient response and outcome, have profoundly improved our knowledge of the molecular mechanisms driving cancer. In GBM, omics have significantly aided in defining the molecular architecture of tumorigenesis, uncovering relevant subsets of patients whose disease may require different treatments. In this review, we focus on the unique advantages of multifaceted omics technologies and discuss the implications on translational GBM research.http://www.brjnmims.org/article.asp?issn=2349-3666;year=2015;volume=2;issue=1;spage=6;epage=20;aulast=Maachani;type=0glioblastomaomicsgenomicstranscriptomicsepigenomicsproteomicsmetabolomics |
| spellingShingle | Uday B Maachani Uma Shankavaram Kevin Camphausen Anita Tandle Advances in Omics Technologies in GBM Biomedical Research Journal glioblastoma omics genomics transcriptomics epigenomics proteomics metabolomics |
| title | Advances in Omics Technologies in GBM |
| title_full | Advances in Omics Technologies in GBM |
| title_fullStr | Advances in Omics Technologies in GBM |
| title_full_unstemmed | Advances in Omics Technologies in GBM |
| title_short | Advances in Omics Technologies in GBM |
| title_sort | advances in omics technologies in gbm |
| topic | glioblastoma omics genomics transcriptomics epigenomics proteomics metabolomics |
| url | http://www.brjnmims.org/article.asp?issn=2349-3666;year=2015;volume=2;issue=1;spage=6;epage=20;aulast=Maachani;type=0 |
| work_keys_str_mv | AT udaybmaachani advancesinomicstechnologiesingbm AT umashankavaram advancesinomicstechnologiesingbm AT kevincamphausen advancesinomicstechnologiesingbm AT anitatandle advancesinomicstechnologiesingbm |